At a glance
- Regulatory status
- Testosterone undecanoate injection is an FDA-approved prescription medicine for testosterone replacement therapy in adult males with conditions associated with a deficiency or absence of endogenous testosterone. It carries a boxed warning for serious pulmonary oil microembolism reactions and anaphylaxis, and in the US it is given only in certified healthcare settings under an FDA safety program (REMS).[3]
- Half-life
- A mean of 33.9 days (SEM 4.9) in 14 hypogonadal men after one 1000 mg intramuscular injection of testosterone undecanoate in castor oil; the US label gives no half-life.[2]
- Route
- Intramuscular, per the label.[3]
- Category
- Testosterone & TRT
- Vial size
- 750 mg
Undecanoate's record concerns a long-acting intramuscular depot. The cited single-use vial holds 750 mg in 3 mL. Neither that package nor the castor-oil half-life study establishes equivalent behavior for another formulation sharing the ester name.[3][2]
What the research says
The cited study investigated intramuscular testosterone undecanoate in forty men with hypogonadism. An initial randomized comparison with testosterone enanthate was followed by longer observation of participants receiving undecanoate. Researchers repeatedly measured serum testosterone and related hormones to characterize the depot formulation over time.[1]
The report follows pharmacokinetics for approximately two and a half years. Measurements included trough testosterone, dihydrotestosterone, and estradiol, with schedules defined by the research design. The publication's main subject is the concentration pattern during long-term administration, rather than package-count or syringe-volume arithmetic.[1]
The study used a particular undecanoate formulation and cannot establish identical behavior for every ester or delivery system. The approved US solution cited separately for package facts is a distinct presentation. Keeping study formulation and label concentration separate preserves the provenance of each number.[1][3]
Cited amounts
The cited label lists a single-use vial of 750 mg in 3 mL (250 mg/mL). This is the total in that presentation, not an amount selected for administration. No personal dosing range is inferred from it.[3]
Open the calculator for amount conversionsHalf-life and timing
A mean of 33.9 days (SEM 4.9) in 14 hypogonadal men after one 1000 mg intramuscular injection of testosterone undecanoate in castor oil; the US label gives no half-life.[2]
Continue to the calculatorReconstitution
The cited vial is single use: 750 mg in 3 mL (250 mg/mL). This is an already prepared oil presentation rather than a powder-reconstitution exercise, and it calls for no additional liquid.[3]
Tracking it in PinPoint
From a reference to a record
Built for peptide, TRT, and GLP-1 schedules. Set up your vial in seconds, log every dose, and see your modeled levels between doses. Track vials and prefilled pens side by side.[4]
The Home curve models your levels between doses from an estimate built on the half-life value stored for each compound, published where a published value exists and an estimate where none does. Drag to scrub modeled values at any timestamp, or preview 30 days of a dose pattern. Ask PinPoint provides educational reference with sources; it never recommends a dose or a schedule change. These features record and visualize entered information, with the limits of each compound's source data still applying.
Get PinPoint on the App StoreFrequently asked questions
- How is testosterone undecanoate vial concentration calculated?
- The referenced 750 mg in 3 mL gives 250 mg/mL by division. It is a prepared intramuscular presentation. The half-life is a separate timing quantity and is not involved in calculating the concentration of the vial.[3]
- Does testosterone undecanoate's generic name identify every formulation's timing?
- The cited half-life study used intramuscular testosterone undecanoate in castor oil. A shared ester name does not supply matching pharmacokinetic data for every possible presentation. The guide therefore keeps the recorded route attached to the cited figure.[2]
Sources
Sources checked against the cited documents on 19 November 2026.
- Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism, 2004 (PubMed 15531493)Abstract read 19 November 2026 (open-label, randomized, 40 hypogonadal men; about 2.5 years of pharmacokinetic follow-up). Gives no half-life. Full text returned HTTP 403.Retrieved 2026-11-19 · human-study
- Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies, 1999 (PubMed 10229906)Abstract read 19 November 2026: study II, 1000 mg in castor oil (250 mg/ml) into one gluteal muscle of 14 patients; half-life 33.9 +/- 4.9 days (mean +/- SEM).Retrieved 2026-11-19 · human-study
- Testosterone undecanoate injection prescribing information (DailyMed, SPL effective 15 July 2025)Read 19 November 2026: boxed warning, 1, 2, 3, 4, 12.3, 16. Single-use vial; REMS; gives no half-life.Retrieved 2026-11-19 · label
- PinPoint App Store descriptionFeature wording from the approved application description, not pricing.Retrieved 2026-10-05 · app-description
